Chuang He1, Hualong Yu2, Changyi Li3, Xin Zhang4, Zhicheng Huang5, Mingyang Liu6, Lunbing Tong7, Jun Zhu8, Wei Wu9, Xuequan Huang1. 1. Treatment Center of Minimally Invasive Intervention and Radioactive Particles, First Affiliated Hospital of the Army Medical University, Chongqing, China. 2. Department of Radiology, Affiliated Hospital of Qingdao University, Qingdao, China. 3. Department of Respiratory, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. 4. Department of Thoracic Surgery, General Hospital of Heilongjiang Province Land Reclamation Bureau, Harbin, China. 5. Department of Radiology, Jilin Provincial Cancer Hospital, Changchun, China. 6. Department of Oncology, General Hospital of Heilongjiang Province Land Reclamation Bureau, Harbin, China. 7. Department of Radiology, Sichuan Police Force Hospital, Leshan, China. 8. Department of Radiology, The Second People's Hospital of Yibin, Yibin, China. 9. Department of Thoracic Surgery, First Affiliated Hospital of the Army Medical University, Chongqing, China.
Abstract
BACKGROUND: Whether preoperative biopsy before radical resection can lead to recurrence and impact patient survival in non-small cell lung cancer (NSCLC) remains controversial. In this study, we carried out a retrospective analysis to determine whether preoperative biopsy can cause disease recurrence and influence disease-free survival (DFS) in patients with stage IA NSCLC. METHODS: Patients diagnosed with stage IA NSCLC (solid nodule) between January 2010 and December 2014 were identified from the databases of 7 Chinese medical centers and divided into two groups: a preoperative computed tomography (CT)-guided needle biopsy (CTNB) plus radical resection group, and a non-CTNB group. The propensity score matching (PSM) method was adopted to balance the observed covariates, and Kaplan-Meier estimates were used for survival analysis. Cox regression was used in a single-factor analysis to identify the factors affecting DFS in stage IA NSCLC. RESULTS: After initial screening, 730 patients were enrolled in this study, with 186 and 544 patients in the CTNB group and the non-CTNB group, respectively. After PSM, 186 patients were eventually included in each group. No significant differences in basic clinical features were identified between the two groups (P>0.05). The rates of recurrence were 17.2% and 14.0% in the CTNB and non-CTNB groups (χ2=0.735, P=0.391), respectively. No notable differences in DFS (χ2=1.895, P=0.173) or overall survival (OS, χ2=1.785, P=0.182) were observed. Lung adenocarcinoma [hazard ratio (HR), 0.167, P=0.001] and lesion size (>2 cm) (HR, 2.712, P=0.000) were identified as risk factors for DFS in stage IA NSCLC. CONCLUSIONS: CTNB does not increase the incidence of recurrence in stage IA NSCLC or affect patient survival; therefore, it is not a risk factor for DFS. Lung adenocarcinoma and lesion size are risk factors for DFS. 2021 Quantitative Imaging in Medicine and Surgery. All rights reserved.
BACKGROUND: Whether preoperative biopsy before radical resection can lead to recurrence and impact patient survival in non-small cell lung cancer (NSCLC) remains controversial. In this study, we carried out a retrospective analysis to determine whether preoperative biopsy can cause disease recurrence and influence disease-free survival (DFS) in patients with stage IA NSCLC. METHODS: Patients diagnosed with stage IA NSCLC (solid nodule) between January 2010 and December 2014 were identified from the databases of 7 Chinese medical centers and divided into two groups: a preoperative computed tomography (CT)-guided needle biopsy (CTNB) plus radical resection group, and a non-CTNB group. The propensity score matching (PSM) method was adopted to balance the observed covariates, and Kaplan-Meier estimates were used for survival analysis. Cox regression was used in a single-factor analysis to identify the factors affecting DFS in stage IA NSCLC. RESULTS: After initial screening, 730 patients were enrolled in this study, with 186 and 544 patients in the CTNB group and the non-CTNB group, respectively. After PSM, 186 patients were eventually included in each group. No significant differences in basic clinical features were identified between the two groups (P>0.05). The rates of recurrence were 17.2% and 14.0% in the CTNB and non-CTNB groups (χ2=0.735, P=0.391), respectively. No notable differences in DFS (χ2=1.895, P=0.173) or overall survival (OS, χ2=1.785, P=0.182) were observed. Lung adenocarcinoma [hazard ratio (HR), 0.167, P=0.001] and lesion size (>2 cm) (HR, 2.712, P=0.000) were identified as risk factors for DFS in stage IA NSCLC. CONCLUSIONS: CTNB does not increase the incidence of recurrence in stage IA NSCLC or affect patient survival; therefore, it is not a risk factor for DFS. Lung adenocarcinoma and lesion size are risk factors for DFS. 2021 Quantitative Imaging in Medicine and Surgery. All rights reserved.
Entities:
Keywords:
Computed tomography-guided needle biopsy (CTNB); disease-free survival (DFS); stage IA non-small cell lung cancer (stage IA NSCLC)
Authors: Seong Mi Moon; Dae Geun Lee; Na Young Hwang; Soohyun Ahn; Hyun Lee; Byeong-Ho Jeong; Yong Soo Choi; Young Mog Shim; Tae Jeong Kim; Kyung Soo Lee; Hojoong Kim; O Jung Kwon; Kyung Jong Lee Journal: Lung Cancer Date: 2017-07-12 Impact factor: 5.705